VolitionRx Limited (NYSE American: VNRX) announced a significant breakthrough in liquid biopsy technology, achieving over 99% purity in isolating circulating tumor-derived DNA (ctDNA) using its proprietary Capture-Seq platform. This advancement addresses a longstanding challenge in the field: distinguishing cancer DNA from healthy cell-free DNA in blood samples. The company reported strong early validation results, including no false positives and successful detection across initial study cohorts, supporting the potential of the technology as a novel biomarker approach.
The achievement could enable more accurate and earlier detection of cancer, as well as monitoring of minimal residual disease (MRD) after treatment. The combined total addressable market for multi-cancer early detection and MRD monitoring is estimated at approximately $36 billion. VolitionRx is in active discussions with global diagnostic and liquid biopsy companies to accelerate development and commercialization of the platform.
According to the company, the Capture-Seq platform uses a unique method to isolate and enrich ctDNA, achieving purity levels that were previously unattainable. This breakthrough could overcome one of the major hurdles in liquid biopsy, where the abundance of normal cell-free DNA often masks the presence of tumor-derived DNA, leading to false negatives or reduced sensitivity.
VolitionRx is a multinational company focused on advancing the science of epigenetics. Through its subsidiaries, it develops and commercializes simple, cost-effective blood tests to detect and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. The company's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.
For more information, visit the company's website at https://volition.com/.
To view the full press release, visit https://ibn.fm/1ZqGi.
